Brilliant Violet 510 anti-human CD69 and 5 more items

BioLegend Inc. was awarded a contract by the University of Virginia on September 26, 2026, for the procurement of specialized laboratory reagents and antibodies. The cumulative contract value is $2,023.55. The contract encompasses six line items of flow cytometry reagents and controls, all of which will be delivered to Ryan M. Sangston at the University of Virginia in Virginia. The awarded items include Brilliant Violet 510 anti-human CD69 antibodies (3 units at $292.60 each), Brilliant Violet 421 anti-human HLA-E antibodies (1 unit at $270.20), PE Mouse IgG1 isotype controls (2 units at $50.05 each), FITC anti-human T-cell receptor V region 13.1 antibodies (2 units at $209.95 each), PE anti-human T-cell receptor V region 13.1 antibodies (1 unit at $221.65), and Alexa Fluor 488 Streptavidin (1 unit at $133.90).

This procurement represents a research support contract supplying immunological reagents essential for flow cytometric analysis and immune cell characterization studies. The specific antibodies and controls specified indicate applications in human immunology research, likely for studying T-cell populations and immune phenotyping. No specific contract performance period is indicated in the available documentation beyond the award date of September 26, 2026.